Bristol-Myers Squibb and AstraZeneca do not review the information on this Web site and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the Web site and/or database producer.

Bristol-Myers Squibb and AstraZeneca make no representation as to the accuracy or any other aspect of the information contained on such Web site and/or database, nor does Bristol-Myers Squibb or AstraZeneca necessarily endorse such Web site and/or database.

Bristol-Myers Squibb and AstraZeneca do not review the information on this Web site and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the Web site and/or database producer.

Bristol-Myers Squibb and AstraZeneca make no representation as to the accuracy or any other aspect of the information contained on such Web site and/or database, nor does Bristol-Myers Squibb or AstraZeneca necessarily endorse such Web site and/or database.

Bristol-Myers Squibb and AstraZeneca do not review the information on this Web site and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the Web site and/or database producer.

Bristol-Myers Squibb and AstraZeneca make no representation as to the accuracy or any other aspect of the information contained on such Web site and/or database, nor does Bristol-Myers Squibb or AstraZeneca necessarily endorse such Web site and/or database.

Bristol-Myers Squibb and AstraZeneca do not review the information on this Web site and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the Web site and/or database producer.

Bristol-Myers Squibb and AstraZeneca make no representation as to the accuracy or any other aspect of the information contained on such Web site and/or database, nor does Bristol-Myers Squibb or AstraZeneca necessarily endorse such Web site and/or database.

Bristol-Myers Squibb and AstraZeneca do not review the information on this Web site and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the Web site and/or database producer.

Bristol-Myers Squibb and AstraZeneca make no representation as to the accuracy or any other aspect of the information contained on such Web site and/or database, nor does Bristol-Myers Squibb or AstraZeneca necessarily endorse such Web site and/or database.

Bristol-Myers Squibb and AstraZeneca do not review the information on this Web site and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the Web site and/or database producer.

Bristol-Myers Squibb and AstraZeneca make no representation as to the accuracy or any other aspect of the information contained on such Web site and/or database, nor does Bristol-Myers Squibb or AstraZeneca necessarily endorse such Web site and/or database.

Bristol-Myers Squibb and AstraZeneca do not review the information on this Web site and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the Web site and/or database producer.

Bristol-Myers Squibb and AstraZeneca make no representation as to the accuracy or any other aspect of the information contained on such Web site and/or database, nor does Bristol-Myers Squibb or AstraZeneca necessarily endorse such Web site and/or database.

Bristol-Myers Squibb and AstraZeneca do not review the information on this Web site and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the Web site and/or database producer.

Bristol-Myers Squibb and AstraZeneca make no representation as to the accuracy or any other aspect of the information contained on such Web site and/or database, nor does Bristol-Myers Squibb or AstraZeneca necessarily endorse such Web site and/or database.

Diabetes Resources

Please see the following useful Web sites for information on type 2 diabetes:

American Association of Clinical Endocrinology (AACE)
The AACE Web site hosts an Inpatient Glycemic Control Resource Center, prescription assistance information, and offers help on finding an endocrinologist and understanding your disorder.

American Association of Diabetes Educators (AADE)
The AADE Web site offers the ability to conduct a diabetes educator search. Included are patient resources, public policy, and advocacy information.

American Diabetes Association (ADA)
Focusing on help, hope, and support, the ADA Web site offers information on diabetes; helping people adjust to living with diabetes; nutritional and fitness guidelines; how to help by donating or volunteering; information on community events; and news and research.

American Dietetic Association
The American Dietetic Association Web site offers food and nutrition information for consumers, event opportunities, and an online store for a variety of related books and publications.

Centers for Disease Control and Prevention (CDC)
The CDC Web site offers information for the public and professionals about diabetes, including research, statistics, and educational publications.

Centers for Medicare & Medicaid Services (CMS)
The CMS Web site provides program and services information on Medicare and Medicaid.

National Diabetes Education Program (NDEP)
Sponsored by the US Department of Health and Human Services' National Institutes of Health and the Centers for Disease Control and Prevention, the NDEP Web site provides diabetes publications and information to a variety of audiences including people with diabetes.

National Diabetes Information Clearinghouse (NDIC)
The NDIC offers diabetes disease and treatment information, as well as statistical data; research, clinical trial information and treatment guidelines; links to diabetes-related resources; access to the National Diabetes Education program (NDEP); and publications.

Want to know more?

Are you a caregiver? Get the information you need to help make a difference

IMPORTANT INFORMATION ABOUT ONGLYZA™ (saxagliptin)

Approved Uses

ONGLYZA™ (saxagliptin) is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes mellitus.

ONGLYZA has not been studied with insulin.

ONGLYZA should not be used to treat people with type 1 diabetes or to treat diabetic ketoacidosis (dangerously high levels of certain acids, known as ketones, in the blood or urine).

Important Safety Information

When ONGLYZA is used with certain other diabetes medicines to treat high blood sugar, such as a sulfonylurea, low blood sugar (hypoglycemia) may occur. Symptoms of low blood sugar include shaking, hunger, sweating, headache, rapid heartbeat, change in mood, and change in vision. Follow your healthcare provider's instructions for treating low blood sugar.

If you have allergic (hypersensitivity) reactions, such as rash, hives, and swelling of the face, lips, and throat, stop taking ONGLYZA and call your healthcare provider right away.

When ONGLYZA is used with a thiazolidinedione (TZD), such as pioglitazone or rosiglitazone, to treat high blood sugar, peripheral edema (fluid retention) may become worse. If you have symptoms of peripheral edema, such as swelling of hands, feet, or ankles, call your healthcare provider.

The most common side effects with ONGLYZA include upper respiratory tract infection, urinary tract infection, and headache.

Your healthcare provider should test your blood to measure how well your kidneys work. You may need a lower dose of ONGLYZA if your kidneys are not working well.

Tell your healthcare provider if you start or stop taking other medications, including antibiotics, antifungals or HIV/AIDS medications, as your healthcare provider may need to change your dose of ONGLYZA.

Tell your healthcare provider if you are pregnant or breast-feeding, or plan to become pregnant or breast-feed.

Please see US Full Prescribing Information, including Patient Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Bristol-Myers Squibb and AstraZeneca do not review the information on this Web site and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the Web site and/or database producer.

Bristol-Myers Squibb and AstraZeneca make no representation as to the accuracy or any other aspect of the information contained on such Web site and/or database, nor does Bristol-Myers Squibb or AstraZeneca necessarily endorse such Web site and/or database.

Bristol-Myers Squibb and AstraZeneca do not review the information on this Web site and/or database for content, accuracy, or completeness. Use of and access to this information is subject to the terms, limitations, and conditions set by the Web site and/or database producer.

Bristol-Myers Squibb and AstraZeneca make no representation as to the accuracy or any other aspect of the information contained on such Web site and/or database, nor does Bristol-Myers Squibb or AstraZeneca necessarily endorse such Web site and/or database.